Press Releases Category

Strategy, appointments, major clinical, medical and regulatory advances, and partnerships: you can find all the latest Ipsen Group press releases here.

April 7, 2025

The Scottish Medicines Consortium (SMC) accepts Ipsen’s IQIRVO® (elafibranor) for use in NHS Scotland – the first new medicine in nearly a decade for primary biliary cholangitis (PBC), a rare liver disease

Press Releases Category News Article

October 22, 2024

NICE recommends Ipsen’s IQIRVO® (elafibranor) – the first medicine approved for NHS use in nearly a decade for primary biliary cholangitis (PBC), a rare liver disease

Press Releases Category News Article

October 8, 2024

U.K. MHRA grants marketing authorisation for Ipsen’s Iqirvo® (elafibranor), a first-in-class peroxisome proliferator-activated receptor (PPAR) treatment for primary biliary cholangitis (PBC)

Press Releases Category News Article

March 7, 2024

Ipsen appoints Ioana Parsons as General Manager, U.K. & Ireland

Press Releases Category News Article

June 15, 2023

Ipsen Wrexham investment unveiled as Wrexham mayor joins 50th birthday celebration

Press Releases Category News Article

April 6, 2023

Ipsen’s response to NICE’s decision on Cabometyx® (cabozantinib) for previously treated differentiated thyroid cancer unsuitable for or refractory to radioactive iodine

Press Releases Category News Article

November 10, 2022

NICE recommends Cabometyx® (cabozantinib) for previously treated advanced hepatocellular carcinoma

Press Releases Category News Article

October 4, 2022

Tánaiste joins Ipsen Ireland to launch upgraded manufacturing site in Blanchardstown

Press Releases Category News Article

June 30, 2022

Ipsen announced overall Pharma Industry Company of the Year in 2021 Pharma Industry Awards

Press Releases Category News Article

© Ipsen Group 2024